Immunologic response to administration of standardized dog allergen extract at differing doses - 20/08/11
, Ronald Harbeck, PhD a, Matthew Strand, PhD, Michael Sills, BS, Kimberly Schmidt, RN, BSN, Benjamin Efaw, MS, Terri Lebo, BS, Harold S. Nelson, MD a
Reprint requests: Anne M. Lent, MD, Division of Allergy and Clinical Immunology, National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206.Denver, Colo
Abstract |
Background |
The immunologic response to immunotherapy with dog extract is not well characterized.
Objective |
The purpose of this study was to examine the immunologic response to 3 doses of dog extract expressed as their Can f 1 content.
Methods |
Cluster immunotherapy was administered to 28 patients with dog allergy who were randomly assigned to 1 of 4 treatment arms: placebo or acetone-precipitated extract containing 0.6 μg, 3.0 μg, or 15.0 μg Can f 1 per 0.5 mL maintenance dose. Studies included titrated skin prick tests, the late cutaneous response, titrated nasal challenge with dog extract, and serum allergen-specific IgE and IgG4. Dog allergen-stimulated lymphocyte proliferation was performed with measurement of secreted cytokines by ELISA and of intracellular cytokines by flow cytometry.
Results |
There was a significant dose-dependent response in suppression of titrated skin prick tests and suppression of the late cutaneous response. There was a significant increase from baseline in dog-specific IgG4 in both the high-dose and low-dose groups and a dose-dependent suppression of secreted TNF-⍺ and increase in secreted TGF-β. There was a dose-dependent trend in suppression of secreted IL-4 with a significant decrease from baseline in the high-dose group. There were no significant changes in symptom scores; lymphocyte proliferation; secreted IFN-γ, IL-10, or IL-5; or intracellular cytokine production.
Conclusion |
The dose-response in immunologic parameters after immunotherapy with dog extract is similar to that previously demonstrated with cat extract.
Clinical implications |
The greatest and most consistent response is seen with a dose containing 15 μg Can f 1.
Le texte complet de cet article est disponible en PDF.Key words : Immunotherapy, acetone-precipitated dog extract, Can f 1, cytokine, allergen-specific IgE, allergen-specific IgG4, skin prick test, late cutaneous response
Abbreviations used : AP, cpm, SPT
Plan
| Supported in part by a grant from the Hollister-Stier Laboratories, Spokane, Wash. Disclosure of potential conflict of interest: A. M. Lent has received grant support from Hollister-Stier Laboratories and is on the speakers’ bureau for GlaxoSmithKline. H. S. Nelson has received grant support from Hollister-Stier Laboratories. The rest of the authors have declared that they have no conflict of interest. |
Vol 118 - N° 6
P. 1249-1256 - décembre 2006 Retour au numéro
Article précédent
- The PTGDR gene is not associated with asthma in 3 ethnically diverse populations
- Yuhjung J. Tsai, Shweta Choudhry, Jennifer Kho, Kenneth Beckman, Hui-Ju Tsai, Daniel Navarro, Henry Matallana, Richard A. Castro, Craig M. Lilly, Sylvette Nazario, Jose R. Rodriguez-Santana, Jesus Casal, Alfonso Torres, Jorge Salas, Rocio Chapela, H. George Watson, Kelley Meade, Pedro C. Avila, William Rodriguez-Cintron, Michael LeNoir, Esteban González Burchard, on behalf of the Genetics of Asthma in Latino Americans Study and the Study of African Americans, Asthma, Genes and Environments Investigators
- Multiple chemical sensitivities: A systematic review of provocation studies
- Jayati Das-Munshi, G. James Rubin, Simon Wessely
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?